ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36165
-0.01%
Bitcoin
66,899.69
-0.27%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cassava Sciences Inc (SAVA)

  7. Cassava Sciences Inc (SAVA) News

SAVA

Cassava Sciences (SAVA)

Cassava Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SAVA
DateTimeSourceHeadlineSymbolCompany
05/10/20243:02PMGlobeNewswire Inc.Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamNASDAQ:SAVACassava Sciences Inc
05/08/202410:00AMGlobeNewswire Inc.Cassava Sciences Announces Over $125 Million Raised from Warrant DistributionNASDAQ:SAVACassava Sciences Inc
05/01/20248:10AMGlobeNewswire Inc.Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQNASDAQ:SAVACassava Sciences Inc
04/15/20248:20AMGlobeNewswire Inc.Redemption Date Announced for WarrantsNASDAQ:SAVACassava Sciences Inc
03/25/20248:13AMGlobeNewswire Inc.Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsNASDAQ:SAVACassava Sciences Inc
03/04/20248:15AMGlobeNewswire Inc.Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International ConferenceNASDAQ:SAVACassava Sciences Inc
02/28/20243:01PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SAVACassava Sciences Inc
02/28/20248:22AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
02/28/20248:14AMGlobeNewswire Inc.Cassava Sciences Reports Full-year 2023 Financial Results and Corporate UpdatesNASDAQ:SAVACassava Sciences Inc
02/07/20248:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
02/07/20248:08AMGlobeNewswire Inc.No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 MonthsNASDAQ:SAVACassava Sciences Inc
02/01/20243:00PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SAVACassava Sciences Inc
01/26/20243:23PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SAVACassava Sciences Inc
01/05/20248:12AMGlobeNewswire Inc.Cassava Sciences Completes Dividend Distribution of Warrants to ShareholdersNASDAQ:SAVACassava Sciences Inc
01/03/20243:24PMEdgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNASDAQ:SAVACassava Sciences Inc
01/03/20243:22PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:SAVACassava Sciences Inc
01/03/20243:18PMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:SAVACassava Sciences Inc
01/03/20248:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
01/02/20248:10AMEdgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:SAVACassava Sciences Inc
12/12/20238:19AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
12/12/20238:13AMGlobeNewswire Inc.Cassava Sciences Announces Dividend Distribution of Warrants to ShareholdersNASDAQ:SAVACassava Sciences Inc
12/11/20233:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
12/08/20234:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/08/20234:04PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/07/20233:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/07/20233:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/07/20233:52PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/07/20233:24PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
12/07/20233:01PMGlobeNewswire Inc.Cassava Sciences Appoints Three New Members to its Board of DirectorsNASDAQ:SAVACassava Sciences Inc
11/07/20238:19AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SAVACassava Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:SAVA

Your Recent History

LSE
17PA
Qnb Fin 26
NYSE
CCV.WS
Churchill Capital Corp V
ASX
PNLDB
Paringa Resources
BOV
D1TE34
DTE Energy
EU
4424T
4424T
UNSW
CPSETH
CashPerScan
BIT
F11477
Vontobel Financial Produ...
USOTC
VGFUF
Vanguard Funds (PK)
LSE
CLIG
City Of London Investment
COIN
HVNUSD
Hiveterminal Token
COIN
1ONEUSD
Harmony ONE
ASX
GFY
TSXV
TCAP.P
Tri Capital Opportunities
NASDAQ
NISCX
American Beacon NIS Core...
NYSE
FCRW
First Eagle Alternative ...
ASX
BKN
Bradken
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved